425: Israel Acquisitions Corp and Gadfin Amend Business Combination Agreement, Adjusting Valuation and Key Terms

Israel Acquisitions Corp and Gadfin Ltd. have amended their Business Combination Agreement, revising the Company Equity Value to $180 million and clarifying terms for their proposed merger, with NewPubco joining the agreement.

Summary

• Israel Acquisitions Corp (ISRL) and Gadfin Ltd. entered into an amendment to their Business Combination Agreement (BCA) on July 2, 2025.
• Gadfin Regev Holdings Ltd. (NewPubco) has become a party to the BCA through this amendment.
• The amendment removes the requirement for Israel Acquisitions Corp to liquidate immediately following the mergers.
• The Company Equity Value has been revised to $180,000,000.
• Provisions related to 'PCAOB Related Default' and 'Threshold Raised Amount' have been removed from the BCA.
• The maximum dilution calculation has been clarified: NewPubco Ordinary shares issued in consideration of, or exchange for, Sponsor Shares, SPAC Shares, and PIPE Shares (together, 'Covered Shares') shall not exceed 30% of NewPubco's issued and outstanding share capital upon Closing.
• If the 'Covered Shares' exceed the 30% dilution cap, the Sponsor will irrevocably forfeit and surrender up to a maximum of 1,429,000 Sponsor Shares, provided the Sponsor does not hold less than 4,000,000 Sponsor Shares following such forfeiture. If the cap is still exceeded, the parties will negotiate an adjustment.
• The deadline for the independent compensation consultant's Benchmark Analysis for post-closing officer and director remuneration has been extended to September 30, 2025.
• Gadfin has gained a termination right, without penalty, if Israel Acquisitions Corp does not receive a full cash waiver from underwriters for deferred underwriting fees currently owed and outstanding within 30 days of July 2, 2025.
• A confidential draft of a Registration Statement on Form F-4 regarding the proposed business combination was submitted to the SEC on July 2, 2025.

Sentiment

Score: 7

Explanation: The document outlines amendments to a business combination agreement, which generally indicates progress towards closing the deal. The changes address potential hurdles (liquidation, PCAOB default, threshold amount) and clarify terms (dilution, valuation), which are positive steps for transaction certainty. However, the extension of a deadline and the introduction of a new termination right related to underwriting fees introduce minor elements of caution.

Positives

• The removal of the immediate liquidation requirement for Israel Acquisitions Corp post-mergers simplifies the transaction structure and provides greater flexibility.
• The elimination of 'PCAOB Related Default' and 'Threshold Raised Amount' provisions may indicate fewer conditions precedent or hurdles for the merger's completion.
• Clarification of the maximum dilution calculation and the inclusion of a Sponsor forfeiture mechanism provide greater transparency and a defined approach to managing shareholder dilution.
• The submission of a confidential draft Form F-4 to the SEC indicates tangible progress towards the consummation of the business combination.

Negatives

• The extension of the deadline for the Benchmark Analysis for officer and director compensation to September 30, 2025, indicates a delay in finalizing key post-closing governance and remuneration structures.
• The addition of a new termination right for Gadfin, contingent on Israel Acquisitions Corp securing a full cash waiver for deferred underwriting fees, introduces a new potential condition that could prevent the merger's completion.

Risks

• Changes in domestic and foreign business environments.
• Changes in the competitive environment in which Gadfin operates.
• Gadfin's ability to manage its growth prospects, meet its operational and financial targets, and execute its strategy.
• The impact of any economic disruptions, decreased market demand, and other macroeconomic factors, including the effect of a global pandemic, on Gadfin's business, projected results of operations, financial performance, or other financial metrics.
• Gadfin's reliance on its senior management team and key employees.
• Risks related to liquidity, capital resources, and capital expenditures.
• Failure to comply with applicable laws and regulations or changes in the regulatory environment in which Gadfin operates.
• The outcome of any potential litigation, government and regulatory proceedings, investigations, and inquiries that Gadfin may face.
• Assumptions or analyses used for Gadfin's forecasts proving to be incorrect and causing its actual operating and financial results to be significantly below its forecasts, including the inability to sign new contracts or secure necessary financial resources as anticipated.
• The acquisition not occurring as planned and negatively affecting operating results.
• The inability of the parties to successfully or timely consummate the Transactions, including the risk that any required regulatory approvals are not obtained, are delayed, or are subject to unanticipated conditions that could adversely affect NewPubco or the expected benefits of the Transactions.
• The risk that the approval of the shareholders of Israel Acquisitions Corp is not obtained.
• The risk that shareholders of Israel Acquisitions Corp could elect to have their shares redeemed, thus leaving NewPubco with insufficient cash to complete the Transactions or grow its business.
• Failure to realize the anticipated benefits of the Transactions.
• Risks relating to the uncertainty of the projected financial information with respect to Gadfin.
• The effects of competition.
• Changes in applicable laws or regulations.
• The ability of Gadfin to manage expenses and recruit and retain key employees.
• The ability of Israel Acquisitions Corp or NewPubco to issue equity or equity-linked securities in connection with the Transactions or in the future.
• A potential U.S. government shutdown.
• The impact of certain geopolitical events, including wars in Ukraine and the surrounding region, the war between Israel and Hamas, the war between Israel and Iran, and conflict in the Middle East.
• The impact of a future pandemic on Gadfin, Israel Acquisitions Corp, or NewPubco's projected results of operations, financial performance, or other financial metrics.

Future Outlook

The parties anticipate successfully consummating the Transactions, including the business combination, and have submitted a confidential draft Registration Statement on Form F-4 to the SEC. Future events and developments may cause assessments to change, and the parties specifically disclaim any obligation to update forward-looking statements.

Management Comments

• Gadfin and ISRL anticipate that subsequent events and developments will cause Gadfins and ISRLs assessments to change.
• While Gadfin and ISRL may elect to update these forward-looking statements at some point in the future, Gadfin and ISRL specifically disclaim any obligation to do so.

Industry Context

This amendment reflects ongoing efforts within the SPAC market to finalize business combinations, often involving adjustments to initial terms to address regulatory requirements, valuation considerations, and financing conditions. The inclusion of a new termination right related to underwriting fees highlights the financial complexities and diligence required in de-SPAC transactions, particularly concerning outstanding obligations.

Corporate Governance

Stakeholder Impact

• Shareholders of Israel Acquisitions Corp will be required to vote on the Transactions and face potential share redemption risk, while also being subject to the clarified dilution terms.
• Shareholders of Gadfin and NewPubco will become shareholders of the combined entity, subject to the revised Company Equity Value and dilution terms.
• Underwriters involved in the initial public offering of Israel Acquisitions Corp are directly impacted by the requirement for a full cash waiver of deferred underwriting fees, which is now a condition for the merger's continuation.
• Future management and directors of the combined company will have their compensation packages reviewed and potentially adjusted based on an independent benchmark analysis.

Next Steps

• The Company and Gadfin will continue to work towards consummating the Business Combination.
• The confidential draft Registration Statement on Form F-4 will undergo SEC review, followed by public filing and distribution of the definitive proxy statement/prospectus to Israel Acquisitions Corp shareholders.
• Israel Acquisitions Corp shareholders will need to vote on the Transactions.
• The independent compensation consultant will present the Benchmark Analysis for officer and director compensation by September 30, 2025.
• Israel Acquisitions Corp needs to receive a full cash waiver from underwriters for deferred underwriting fees within 30 days of July 2, 2025, to avoid Gadfin's termination right.

Key Dates

Keywords

Business Combination Agreement, Merger Agreement Amendment, SPAC, De-SPAC, Israel Acquisitions Corp, Gadfin Ltd., NewPubco, Company Equity Value, Share Dilution, SEC Filing, Form 425, Corporate Governance, Underwriting Fees, Transaction Terms